China uses new drug for lymphoma

China has approved the use of the innovative drug "Rocurveitinib" for the treatment of lymphoma, particularly for patients who have developed resistance to other medications. The drug works by targeting and inhibiting the PTK protein within cancer cells, maintaining its effectiveness even in cases involving mutations that cause drug resistance. Clinical trials have shown that the drug achieves an overall response rate of 63.9%, with 23% of cases experiencing a complete response. The average duration of response was 16.5 months, providing a new option for patients with limited treatment choices.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل